| Item | Key numbers/findings | Population/context | Source (URL; year) | Evidence citation id |
|---|---|---|---|---|
| Incidence / rarity | Incidence reported at ~0.061 per 100,000/year; also described as 1–2 per million people/year; SFTs account for **<2% of soft tissue tumors/masses** | General / extrameningeal SFT in reviews | Janik et al., *Cancers* (https://doi.org/10.3390/cancers15245854; 2023); Ren et al., *Cancer Metastasis Rev.* (https://doi.org/10.1007/s10555-024-10204-8; 2024) | (pqac-00000003, pqac-00000002) |
| Recurrence / metastasis rates | Reviews cite **10–30%** recurrence after resection; recurrence/metastasis rate broadly **10–40%**; longer-follow-up cohorts may report recurrence **>30%** | Mixed non-CNS SFT cohorts, especially resected torso/extremity disease | Tolstrup et al., *Front Surg* (https://doi.org/10.3389/fsurg.2024.1332421; 2024); Zhang et al., *Nat Commun* (https://doi.org/10.1038/s41467-023-43249-4; 2023) | (pqac-00000017, pqac-00000016, pqac-00000008) |
| SEER malignant SFT cohort | **n=1,134** malignant SFTs; sites: chest **28–29%**, CNS **22–23%**, head/neck **11%**, pelvis **11%**, extremities **10%**, abdomen **10%**, retroperitoneum **6%**; stage: localized **42%**, locally advanced **35%**, metastatic **13%**; surgery in **87%** | SEER 2000–2019 malignant SFT population-based cohort | Piccinelli et al., *Cancers* (https://doi.org/10.3390/cancers16193331; 2024) | (pqac-00000007, pqac-00000014, pqac-00000015) |
| SEER prognostic factors | Higher cancer-specific mortality with locally advanced stage **HR 1.6**, metastatic stage **HR 2.9**, non-surgical management **HR 3.6**, tumor size **9–15.9 cm HR 1.6**, **≥16 cm HR 1.9** | Multivariable competing-risks analysis in SEER malignant SFT cohort | Piccinelli et al., *Cancers* (https://doi.org/10.3390/cancers16193331; 2024) | (pqac-00000007, pqac-00000015) |
| CNS WHO grade outcomes | Grade 1: median **PFS 105 mo**, **OS 199 mo**; Grade 2: **PFS 77 mo**, **OS 145 mo**; Grade 3: **PFS 44 mo**, **OS 112 mo**; cohort counts: grade 1 **86**, grade 2 **35**, grade 3 **25** | Reclassified CNS SFT/HPC cohort, **n=146**, per WHO 2021 CNS classification | Wu et al., *J Neurosurg* (https://doi.org/10.3171/2023.4.JNS23147; 2024) | (pqac-00000001) |
| CNS recurrence / mortality / treatment effect | Local recurrence in **61/146**; deaths **31/146**, of which **27/31 (87.1%)** disease-related; subtotal resection worsened PFS (**HR 4.648**) and OS (**HR 3.217**); grade 3 worsened PFS (**HR 5.814**) and OS (**HR 3.433**) | Same CNS cohort | Wu et al., *J Neurosurg* (https://doi.org/10.3171/2023.4.JNS23147; 2024) | (pqac-00000001) |
| Pleural malignant SFT outcomes | **5-year OS 81.2%**, **5-year DFS 77.4%**; recurrence in **9/34 (26.5%)**; median follow-up **111 months**; median age **67 years** | Single-center cohort of malignant pleural SFT, **n=34** | Ricciardi et al., *J Clin Med* (https://doi.org/10.3390/jcm12030966; 2023) | (pqac-00000019) |
| Pleural malignant SFT prognostic factors | Worse OS: necrosis, nuclear atypia, tumor size **>11.5 cm**, relapse/progression; worse DFS: non-radical resection, larger size, necrosis, nuclear atypia, pleural pattern; Tapias score best predicted OS/DFS | Same malignant pleural SFT cohort | Ricciardi et al., *J Clin Med* (https://doi.org/10.3390/jcm12030966; 2023) | (pqac-00000019) |
| Recurrence risk factors across studies | Most consistent adverse factors: **high mitotic index**, **necrosis**, **high Ki-67 index**; additional variably associated factors: age, tumor size, sex, margins, location, pleomorphism, hypercellularity, dedifferentiation, CD34, TP53, APAF1, TERT promoter mutation, NAB2::STAT6 variant | 81 retrospective studies in systematic review of resected torso/extremity SFT | Tolstrup et al., *Front Surg* (https://doi.org/10.3389/fsurg.2024.1332421; 2024) | (pqac-00000016, pqac-00000017) |
| Modified Demicco model performance caveat | In 111 extrameningeal SFTs, progression still occurred in **3/74 low-risk** and **7/21 intermediate-risk** cases; TP53 alterations: progression in **3/5**; TERT promoter mutations: progression in **3/4** followed cases | East China extrameningeal SFT series, **n=111** | Yao et al., *Front Oncol* (https://doi.org/10.3389/fonc.2023.1272090; 2024) | (pqac-00000008) |
| Demicco risk model variables | WHO-recommended Demicco models use **age**, **tumor size**, **mitotic count**, and in the modified 4-variable model **necrosis** to assign low/intermediate/high metastatic risk | Risk stratification for extrameningeal SFT | Janik et al., *Cancers* (https://doi.org/10.3390/cancers15245854; 2023); image extract of Demicco table | (pqac-00000005, pqac-00000030) |
| WHO/CNS grading variables | CNS WHO grading uses mitotic activity and necrosis: grade 1 **<2.5 mitoses/mm²**, grade 2 **≥2.5 mitoses/mm²**, grade 3 **≥2.5 mitoses/mm² plus necrosis** | WHO 2021 CNS SFT framework | Wu et al., *J Neurosurg* (https://doi.org/10.3171/2023.4.JNS23147; 2024) | (pqac-00000001) |


*Table: This table compiles the main quantitative epidemiology, prognosis, and risk-model findings for solitary fibrous tumor from the gathered evidence. It is useful as a compact reference for incidence, recurrence, survival, and the variables used in current risk stratification systems.*